SG11201811478TA - Freeze-dried formulations of antibacterial protein - Google Patents
Freeze-dried formulations of antibacterial proteinInfo
- Publication number
- SG11201811478TA SG11201811478TA SG11201811478TA SG11201811478TA SG11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA SG 11201811478T A SG11201811478T A SG 11201811478TA
- Authority
- SG
- Singapore
- Prior art keywords
- staphylococcus
- international
- dong
- songpa
- seoul
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 241001478240 Coccus Species 0.000 abstract 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 241001147686 Staphylococcus arlettae Species 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 241001147687 Staphylococcus auricularis Species 0.000 abstract 1
- 241000191965 Staphylococcus carnosus Species 0.000 abstract 1
- 241000201854 Staphylococcus chromogenes Species 0.000 abstract 1
- 241001147698 Staphylococcus cohnii Species 0.000 abstract 1
- 241000520126 Staphylococcus delphini Species 0.000 abstract 1
- 241000191963 Staphylococcus epidermidis Species 0.000 abstract 1
- 241000192085 Staphylococcus gallinarum Species 0.000 abstract 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 abstract 1
- 241000192087 Staphylococcus hominis Species 0.000 abstract 1
- 241001147689 Staphylococcus kloosii Species 0.000 abstract 1
- 241000147121 Staphylococcus lentus Species 0.000 abstract 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 abstract 1
- 241000192101 Staphylococcus muscae Species 0.000 abstract 1
- 241000193817 Staphylococcus pasteuri Species 0.000 abstract 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 abstract 1
- 241000192086 Staphylococcus warneri Species 0.000 abstract 1
- 241000191973 Staphylococcus xylosus Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002147 killing effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662277588P | 2016-01-12 | 2016-01-12 | |
PCT/IB2017/050091 WO2017122114A1 (fr) | 2016-01-12 | 2017-01-09 | Formulations lyophilisées de protéine antibactérienne |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811478TA true SG11201811478TA (en) | 2019-01-30 |
Family
ID=59310884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811478TA SG11201811478TA (en) | 2016-01-12 | 2017-01-09 | Freeze-dried formulations of antibacterial protein |
Country Status (16)
Country | Link |
---|---|
US (2) | US20190183803A1 (fr) |
EP (1) | EP3402466A4 (fr) |
JP (1) | JP7085482B2 (fr) |
KR (2) | KR20180114011A (fr) |
CN (2) | CN116831993A (fr) |
AU (1) | AU2017208117B2 (fr) |
BR (1) | BR112018014181A2 (fr) |
CA (1) | CA3010565C (fr) |
MX (1) | MX2018008544A (fr) |
MY (1) | MY193907A (fr) |
NZ (1) | NZ749843A (fr) |
RU (2) | RU2708393C1 (fr) |
SG (1) | SG11201811478TA (fr) |
UA (1) | UA125388C2 (fr) |
WO (1) | WO2017122114A1 (fr) |
ZA (1) | ZA201804014B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ749842A (en) * | 2016-01-12 | 2024-11-29 | Intron Biotechnology Inc | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition |
CN111588841A (zh) * | 2019-02-21 | 2020-08-28 | 中国人民解放军军事科学院军事医学研究院 | 一种可气溶胶化的seb类毒素疫苗干粉吸入剂 |
RU2744331C1 (ru) * | 2020-07-07 | 2021-03-05 | Общество с ограниченной ответственностью "ГЕМАТЕК" | Изотонический инфузионный раствор |
WO2022145518A1 (fr) * | 2020-12-29 | 2022-07-07 | 주식회사 바이오빛 | Composition de revêtement dur comprenant une protéine antibactérienne et procédé de préparation associé |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ500539A (en) * | 1995-07-27 | 2001-11-30 | Genentech Inc | An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer |
EP1301601A2 (fr) * | 2000-07-19 | 2003-04-16 | PHARMACIA & UPJOHN COMPANY | Sequence nucleotidique complete du gene de la proteine ribosomale de staphylococcus aureus , s16, et methodes d'identification de substances antibacteriennes |
IE20060488A1 (en) * | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
KR100759988B1 (ko) * | 2006-08-04 | 2007-09-19 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균에 특이적인 항균 단백질 |
KR100910961B1 (ko) * | 2007-09-13 | 2009-08-05 | 주식회사 인트론바이오테크놀로지 | 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질 |
WO2009118754A2 (fr) * | 2008-03-28 | 2009-10-01 | Astron Research Limited | Procédé pour préparer une composition lyophilisée stable |
US8377866B2 (en) * | 2009-02-12 | 2013-02-19 | Intron Biotechnology, Inc. | Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus |
CN103003422B (zh) | 2010-04-20 | 2015-02-11 | 奥克塔法马股份有限公司 | 用于药物蛋白的新型稳定剂 |
CN102648978B (zh) | 2011-04-19 | 2013-09-25 | 杭州九源基因工程有限公司 | 一种稳定的蛋白药物制剂及其制备方法 |
WO2013180316A1 (fr) * | 2012-05-29 | 2013-12-05 | 주식회사 인트론바이오테크놀로지 | Composition pouvant améliorer la stabilité des protéines de lysine de bactériophages |
-
2017
- 2017-01-09 MY MYPI2018002703A patent/MY193907A/en unknown
- 2017-01-09 EP EP17738260.3A patent/EP3402466A4/fr active Pending
- 2017-01-09 CN CN202310739229.6A patent/CN116831993A/zh active Pending
- 2017-01-09 NZ NZ749843A patent/NZ749843A/en active IP Right Revival
- 2017-01-09 US US16/300,567 patent/US20190183803A1/en not_active Abandoned
- 2017-01-09 AU AU2017208117A patent/AU2017208117B2/en active Active
- 2017-01-09 RU RU2018124794A patent/RU2708393C1/ru active
- 2017-01-09 SG SG11201811478TA patent/SG11201811478TA/en unknown
- 2017-01-09 BR BR112018014181-0A patent/BR112018014181A2/pt active Search and Examination
- 2017-01-09 CN CN201780006445.2A patent/CN108463215A/zh active Pending
- 2017-01-09 JP JP2018536378A patent/JP7085482B2/ja active Active
- 2017-01-09 MX MX2018008544A patent/MX2018008544A/es unknown
- 2017-01-09 UA UAA201813043A patent/UA125388C2/uk unknown
- 2017-01-09 KR KR1020187021864A patent/KR20180114011A/ko not_active Application Discontinuation
- 2017-01-09 WO PCT/IB2017/050091 patent/WO2017122114A1/fr active Application Filing
- 2017-01-09 KR KR1020247042520A patent/KR20250004941A/ko active Application Filing
- 2017-01-09 CA CA3010565A patent/CA3010565C/fr active Active
- 2017-01-09 RU RU2019138064A patent/RU2734308C2/ru active
-
2018
- 2018-06-15 ZA ZA2018/04014A patent/ZA201804014B/en unknown
-
2021
- 2021-02-11 US US17/173,867 patent/US20210161821A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7085482B2 (ja) | 2022-06-16 |
AU2017208117A1 (en) | 2018-07-26 |
KR20180114011A (ko) | 2018-10-17 |
CA3010565C (fr) | 2024-05-14 |
WO2017122114A1 (fr) | 2017-07-20 |
ZA201804014B (en) | 2019-04-24 |
MY193907A (en) | 2022-10-31 |
CN108463215A (zh) | 2018-08-28 |
MX2018008544A (es) | 2019-05-15 |
JP2019501931A (ja) | 2019-01-24 |
US20210161821A1 (en) | 2021-06-03 |
CA3010565A1 (fr) | 2017-07-20 |
RU2708393C1 (ru) | 2019-12-06 |
UA125388C2 (uk) | 2022-03-02 |
AU2017208117B2 (en) | 2022-07-14 |
RU2019138064A3 (fr) | 2020-05-29 |
BR112018014181A2 (pt) | 2018-12-26 |
EP3402466A1 (fr) | 2018-11-21 |
RU2019138064A (ru) | 2019-12-06 |
NZ749843A (en) | 2024-09-27 |
KR20250004941A (ko) | 2025-01-08 |
US20190183803A1 (en) | 2019-06-20 |
RU2734308C2 (ru) | 2020-10-15 |
CN116831993A (zh) | 2023-10-03 |
EP3402466A4 (fr) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811478TA (en) | Freeze-dried formulations of antibacterial protein | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
SG11201803951QA (en) | Oligonucleotides for inducing paternal ube3a expression | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201805420SA (en) | Antibodies and conjugates thereof | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201408174UA (en) | Antibody formulation | |
SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
SG11201407284TA (en) | Polypeptide mixes with antibacterial activity | |
SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
SG11201807075QA (en) | A ball launcher and ball gaming system including such ball launcher | |
SG11201810940XA (en) | Methods of treating pancreatic cancer | |
SG11201808804TA (en) | A method to enhance wound healing using silk-derived protein | |
SG11201811479RA (en) | An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201909602TA (en) | Compositions and methods involving probiotic molecules |